Experimental models have also shown that SGLT2 inhibitors, such as empagliflozin and canagliflozin, can reduce peritoneal fibrosis, inflammation, and the microvessel density while enhancing peritoneal ultrafiltration [200,201]. The gene discussed is SLC5A2; the disease is Peritoneal Fibrosis.